Contact information
Department of Medicine II
Hematology/Oncology
University Hospital Frankfurt
Theodor-Stern-Kai 7
60590 Frankfurt am Main
Research Projects
-
A02
The functional role of cytoskeletal dysregulation in activated B cell-like diffuse large B cell lymphoma
Prof. Dr. med. Thomas Oellerich -
C03
Proteogenomic characterization of mantle cell lymphoma
Prof. Dr. med. Reinhard Büttner, Prof. Dr. med. Thomas Oellerich -
Z02
Service project: Multiparametric analysis of lymphoma cells and their microenvironment
Prof. Dr. med. Reinhard Büttner, Prof. Dr. med. Thomas Oellerich, Dr. rer. nat. Nieves Peltzer, Dr. med. Lukas Frenzel, Prof. Dr. med. Dr. rer. nat. Michal Schweiger
CV
Academic education
| 2003 - 2010 | Medical School, University of Göttingen, Germany/Royal Infirmary Edinburgh, UK |
Scientific degrees
| 04/2019 | DKTK W3 Professorship (full professor), Dept. of Medicine II |
| 07/2012 | MD, Institute for Cellular and Molecular Immunology, Georg August University Göttingen. Entitled: The organisation of signaling networks in B cells. Advisor: Prof. Wienands (Grade: Summa cum laude) |
| 06/2010 | Graduation from Medical School, Georg August University Göttingen |
Scientific career
| 2023 - present | Director, Department of Hematology and Oncology, University Hospital Frankfurt |
| 2019 - 2023 | Director, Lymphoma Clinic |
| 2019 - present | Head of the Molecular Diagnostics Program, Frankfurt Cancer Institute |
| 2017 - 2019 | Project leader/Research collaborator, National Cancer Institute, NIH, Lymphoid Malignancies Branch, USA (director: Louis Staudt)) |
| 2015 - 2017 | Project leader/Research collaborator, University of Cambridge, Department of Haematology, UK (director: Tony Green) |
| 2014 - 2018 | Steering committee member, LOEWE Center for Cell and Gene Therapy Frankfurt (CGT, funding: 40.419.080,00 €) |
| 2018 - present | Director DKTK Proteomics Core Facility Frankfurt |
| 2014 - present | Research group leader University Hospital Frankfurt, Department of Hematology/Oncology |
Honors/ Awards/ Memberships
| 2018 | Johann Georg Zimmermann Research Award |
| 2018 | Artur-Pappenheim Research Award |
| 2016 | GILEAD Research Award Oncology |
| 2012 | Publication Award of the Georg August University Göttingen |
| 2002 | Award of the German Society of Physics |
Publications
-
Response to Bruton’s tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy
Diffuse large B cell lymphoma (DLBCL) is an aggressive, profoundly heterogeneous cancer, presenting a challenge for precision medicine. Bruton’s tyrosine kinase (BTK) inhibitors block B cell receptor (BCR) signaling and are particularly effective in certain molecular subtypes of DLBCL that rely on…
-
LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1
Microenvironmental bystander cells are essential for the progression of chronic lymphocytic leukemia (CLL). We have discovered previously that LYN kinase promotes the formation of a microenvironmental niche for CLL. Here we provide mechanistic evidence that LYN regulates the polarization of stromal…
-
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML
Hypomethylating agents decitabine and azacytidine are regarded as interchangeable in the treatment of acute myeloid leukemia (AML). However, their mechanisms of action remain incompletely understood, and predictive biomarkers for HMA efficacy are lacking. Here, we show that the bioactive metabolite…
-
Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia
Spleen tyrosine kinase (SYK) is a nonmutated therapeutic target in acute myeloid leukemia (AML). Attempts to exploit SYK therapeutically in AML have shown promising results in combination with chemotherapy, likely reflecting induced mechanisms of resistance to single-agent treatment in vivo. We…